Ocumetics Technology Corp (TSE:OTC)
:OTC
Want to see TSE:OTC full AI Analyst Report?
OTC Stock Chart & Stats
C$0.55
C$0.02(6.45%)
At close: 4:00 PM EST
C$0.55
C$0.02(6.45%)
Day’s Range― - ―
52-Week RangeC$0.26 - C$1.99
Previous CloseN/A
Volume36.17K
Average Volume (3M)77.99K
Market Cap
C$30.98M
Enterprise ValueC$36.88M
Total Cash (Recent Filing)C$464.04K
Total Debt (Recent Filing)C$5.30M
Price to Earnings (P/E)―
Beta0.71
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding53,414,104
10 Day Avg. Volume70,232
30 Day Avg. Volume77,988
Financial Highlights & Ratios
PEG Ratio-0.23
Price to Book (P/B)-18.65
Price to Sales (P/S)0.00
P/FCF Ratio-21.06
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Specialized Ophthalmic Product FocusA focused product strategy targeting accommodative intraocular lenses concentrates R&D and commercial efforts on a clear clinical need. If the technology proves safe and effective, this specialization supports durable differentiation, targeted go-to-market execution, and clearer regulatory/commercial pathways over months.
Progress Toward Regulatory/commercial MilestonesActive progress toward regulatory approvals and commercialization represents structural de-risking: successful regulatory milestones convert R&D into market access and recurring revenue potential. Over a 2–6 month horizon, continued regulatory momentum materially affects long-term viability.
Improving Free Cash Flow Trend (from Deep Negative)An improving free cash flow trend, even from a negative base, indicates the company is reducing burn or improving operating efficiency. Sustained improvement lessens near-term financing needs and supports runway extension, a durable operational improvement if the trend continues.
Bears Say
No Revenue / Negative Gross ProfitThe absence of revenue and persistent negative gross profit confirm a pre-commercial stance with ongoing product delivery costs but no sales. Over the medium term this means the company must bridge to commercialization via financing, and cannot yet prove demand, unit economics, or sustainable margins.
Persistent Negative Cash GenerationMaterial negative operating and free cash flow reflect ongoing cash burn tied to R&D and operations. Unless reversed, this sustained outflow increases reliance on external financing, raises dilution risk, and constrains investment in clinical/commercial scaling—key long-term execution risks.
Weak Balance Sheet: Negative Equity, Rising DebtNegative shareholders' equity and rapidly increasing debt signal accumulated losses and deteriorating capital structure. Elevated leverage and thin equity cushion reduce financial flexibility, likely increasing borrowing costs and limiting the firm's ability to sustain clinical and commercialization activities without further external funding.
Ocumetics Technology Corp News
OTC FAQ
What was Ocumetics Technology Corp’s price range in the past 12 months?
Ocumetics Technology Corp lowest stock price was C$0.26 and its highest was C$1.99 in the past 12 months.
What is Ocumetics Technology Corp’s market cap?
Ocumetics Technology Corp’s market cap is C$30.98M.
When is Ocumetics Technology Corp’s upcoming earnings report date?
Ocumetics Technology Corp’s upcoming earnings report date is May 20, 2026 which is in 22 days.
How were Ocumetics Technology Corp’s earnings last quarter?
Currently, no data Available
Is Ocumetics Technology Corp overvalued?
According to Wall Street analysts Ocumetics Technology Corp’s price is currently Overvalued.
Does Ocumetics Technology Corp pay dividends?
Ocumetics Technology Corp does not currently pay dividends.
What is Ocumetics Technology Corp’s EPS estimate?
Ocumetics Technology Corp’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Ocumetics Technology Corp have?
Ocumetics Technology Corp has 53,414,104 shares outstanding.
What happened to Ocumetics Technology Corp’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Ocumetics Technology Corp?
Currently, no hedge funds are holding shares in TSE:OTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Ocumetics Technology Corp
Ocumetics Technology Corp., a research and product development company, designs and produces various lenses. Its products include Bionic Lens, an expandable intraocular lens that fits within the natural lens compartment of the eye to eliminate the need for corrective lenses. The company is headquartered in Calgary, Canada.
Technical Analysis
Aurora Spine
―
Covalon Technologies
―
Perimeter Medical Imaging AI
―
VentriPoint Diagnostics
―
Conavi Medical
―